Healthcare Industry News: HSMN NewsFeed
News Release - March 28, 2017
Introducing PROMETHEUS(R) IBcause(TM): Convenient All-in-One Diagnostic Test for Persistent DiarrheaSAN DIEGO, March 28, 2017 -- (Healthcare Sales & Marketing Network) -- Prometheus Laboratories Inc.—a Nestlé Health Science company—announces the launch of IBcause™, an all-in-one convenient test that evaluates a unique combination of 20 stool and serum measures all at 1 time. IBcause will assist healthcare providers in diagnosing many common causes of persistent diarrhea.
"IBcause may help healthcare providers get to a diagnosis faster and a specific treatment plan sooner than sequential testing and empiric treatment for persistent diarrhea," said Warren Cresswell, General Manager and Head of Prometheus Diagnostics (Dx). "IBcause brings many key stool and serum assays together, including a proprietary assay that is not available elsewhere in the United States to test for bile acid malabsorption (BAM). BAM may affect up to 50% of patients with unexplained persistent diarrhea and is often overlooked or misdiagnosed as diarrhea-predominant irritable bowel syndrome (IBS-D)."1,2
A convenient online portal for obtaining fast test results and information for patients, as well as test ordering and results for healthcare providers, is now available at PrometheusOnline.com. Also, as part of Prometheus' ongoing commitment to patient support, new resources have been developed, including a guide, videos, a website, and telephone support to address any patient questions.
"IBcause and the Prometheus Online portal represent our continued commitment to innovation and testing excellence," said Cresswell.
1. Walters JR. Defining primary bile acid diarrhea: making the diagnosis and recognizing the disorder. Expert Rev Gastroenterol Hepatol. 2010;4(5):561-567.
2. Pattni S, Walters JR. Recent advances in the understanding of bile acid malabsorption. Br Med Bull. 2009;92:79-93.
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestlé Health Science in July 2011. Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.
About Nestlé Health Science
Nestlé Health Science, a wholly-owned subsidiary of Nestlé, is a health-science company engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients, and its partners in healthcare. Nestlé Health Science's portfolio of nutrition solutions, diagnostics, devices, and drugs targets a number of health areas, such as inborn errors of metabolism, pediatric and acute care, obesity care, healthy aging as well as gastrointestinal and brain health. Through investing in innovation and leveraging leading edge science, Nestlé Health Science brings forward innovative nutritional therapies with clinical, health economic value, and quality of life benefits. Nestlé Health Science employs around 3,000 people worldwide and is headquartered in Epalinges (near Lausanne), Switzerland. For more information, please visit: www.nestlehealthscience.com.
PROMETHEUS and IBcause are trademarks or registered trademarks of Société des Produits Nestlé S.A. Vevey, Switzerland.
Source: Prometheus Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.